US Orphan Drugs Market

US Orphan Drugs Market Research Report Information By Drug Type (Biologics & Non-Biologics), By Sale (Generics & Prescribed), By Drug (Revlimid, Rituxan, Opdivo, Keytruda, Imbruvica, Soliris, Jakaf, Pomalyst, Darzalex, Spinraza, and Adcetris), By Therapy Class (Oncology, Blood, Central Nervous Systems, Endocrine, Cardiovascular, and Respiratory), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030.

ID: MRFR/Pharma/11599-US | 100 Pages | Author: MRFR Research Team | December 2023         

Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

The U.S. orphan drugs market has witnessed significant growth in recent years, driven by a combination of regulatory support, increasing prevalence of rare diseases, and advancements in medical research. Orphan drugs, designed to diagnose, prevent, or treat rare and life-threatening diseases, have become a focal point for pharmaceutical and biotech companies seeking to address unmet medical needs.

Rare diseases, defined in the U.S. as conditions affecting fewer than 200,000 individuals, collectively impact millions of Americans. Recognizing the challenges faced by the pharmaceutical industry in developing drugs for such a limited patient population, the U.S. government has implemented supportive measures. The Orphan Drug Act, enacted in 1983, provides incentives to encourage the development of orphan drugs, including extended market exclusivity, tax credits, and grants for research and development.

The market dynamics of orphan drugs in the U.S. reveal promising trends. According to market analysis, the U.S. orphan drugs market is expected to register a compound annual growth rate (CAGR) of 11.50% during the forecast period from 2018 to 2023. In 2017, the Americas led the market with a 39.9% share, reflecting the region's commitment to addressing rare diseases. Europe and Asia-Pacific followed with shares of 33.5% and 20.8%, respectively.

The U.S. orphan drugs market has been categorized based on various factors, including drug type, sale, drug, and therapy class. Biologics, accounting for 64.5% of the market share in 2017, have dominated the drug type segment. These drugs, derived from living organisms, have shown significant efficacy in treating rare diseases. The generic segment holds the largest market share in sales, reflecting the cost-effective nature of generic drugs in comparison to their branded counterparts.

Revlimid, a drug used in treating various hematologic conditions, represented a significant market share in the drug segment. Oncology emerged as the dominant therapy class, commanding a 50.0% market share in 2017. This underscores the critical role of orphan drugs in addressing rare forms of cancer and related conditions.

Challenges in the U.S. orphan drugs market include high per-patient treatment costs and regulatory restrictions on profitability. Despite these challenges, the market's growth trajectory remains positive, driven by the ongoing commitment of pharmaceutical companies, government incentives, and the increasing prevalence of rare diseases.

In conclusion, the U.S. orphan drugs market continues to expand, offering hope to individuals affected by rare diseases. The collaborative efforts of government agencies, pharmaceutical companies, and research organizations contribute to the development of innovative treatments, ultimately improving the quality of life for those facing rare and life-threatening conditions.